The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Changes

22 Nov 2022 07:00

RNS Number : 1156H
Byotrol PLC
22 November 2022
 

22 November, 2022

 

Byotrol plc

 

("Byotrol" or the "Company")

 

Directorate Changes

 

 

Byotrol plc, the developer of anti-microbial hygiene technologies, announces the following long-planned board changes.

 

· John Langlands, Non-Executive Chairman since February 2017, has notified the Board of his wish to retire from business and to step-down as Chairman and as a Director of Byotrol. John originally only intended to serve as Chairman of Byotrol for five years, but has remained slightly longer to guide the Company through this year's AGM. John will initially remain as a Non Executive Director to aid the leadership transition, but will then retire as a Director on 31 January 2023, having completed 6 years of service.

· David Traynor, Chief Executive Officer since October 2013 is moving to Executive Chairman, with immediate effect. In addition to his responsibilities as Chairman, David will now focus on securing and developing intellectual property agreements and commercial alliances for the Company.

· Vivan Pinto, currently Byotrol's Chief Growth Officer, and formerly VP and Area MD at Johnson and Johnson Consumer Health, is being promoted to Chief Executive Officer and joins the Board as an Executive Director with immediate effect. He will now assume formal responsibility for the day-to-day sales and operations of the Company, working closely with Chris Sedwell, Executive Director and Chief Financial Officer.

The Board wishes to express formally its sincere thanks to John Langlands for his guidance and advice to the Company over the last six years, during highly volatile market conditions.

 

 

John Langlands, outgoing Non-Executive Chairman, commented:

 

"I have certainly enjoyed my time as Chairman of Byotrol, but with the pandemic now subsiding and the Byotrol team and its technologies so much improved, it is the right time for me to step-down. I will remain a supportive shareholder and will continue to offer the team advice where I can." 

 

David Traynor, incoming Executive Chairman, commented:

 

"We are very grateful to John for his excellent contribution to the Company through some extraordinary times and wish him every happiness in his retirement. We will certainly miss his calm, pragmatic and good-humoured presence in the Company.

 

"I am looking forward to taking over as Chairman of the Company and handing the CEO reins across to Vivan Pinto. Vivan has had a big impact on our business so far and has an excellent track record of building healthy businesses at all operational levels."

Vivan Pinto, incoming Chief Executive Officer, commented:

 

"Byotrol has built an exceptional base of technology platforms, the most recent of which we launched last week at the London Vet Show. I know we can bring those technologies to more customers in more geographies and I am looking forward to making it happen."

 

 

Byotrol Plc

David Traynor - Executive Chairman

Vivan Pinto - Chief Executive Officer

+44 (0)1925 742 000

Chris Sedwell - Chief Financial Officer

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash / George Dollemore - Corporate Finance

Nigel Birks / Harriet Ward - ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

byotrol@flagstaffcomms.com

 

 

 

AIM Rules, Schedule 2(g) disclosures:

In accordance with Schedule 2(g) of the AIM Rules, Vivan Francis Pinto, aged 49, holds or has held, within the last five years, the following directorships and partnerships:

 

Current directorships/partnerships

Past directorships/partnerships

Johnson and Johnson (Pty) Ltd

 

 

At the date of this announcement, Mr Pinto has an interest in 300,000 ordinary shares representing 0.07% of the total voting rights of the Company and 3,076,923 Convertible Loan Notes, which if fully converted would represent an additional 0.68% of the total voting rights of the Company.

 

There is no further information disclosable in respect of Vivan Pinto pursuant to Schedule 2(g) of the AIM rules for companies.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABBBFTMTATBAT
Date   Source Headline
5th Sep 20077:01 amRNSDirector/PDMR Shareholding
4th Sep 20077:00 amRNSDirectorate Change
31st Aug 200710:07 amRNSTotal Voting Rights
16th Aug 20078:41 amRNSAIM RULE 26 INFORMATION
6th Aug 20072:49 pmRNSAdditional Listing
1st Aug 20078:21 amRNSTotal Voting Rights
1st Aug 20077:01 amRNSDirector/PDMR Shareholding
30th Jul 20071:04 pmRNSAGM Statement
30th Jul 20077:01 amRNSJoint Venture
20th Jun 20077:01 amRNSAnnual Report and Accounts
8th Jun 20077:00 amRNSAdditional Listing
4th Jun 20077:00 amRNSNEW GLOBAL CONTRACT
4th May 20077:01 amBUSBYOTROL plc • HEALTHCARE PRODUCT LAUNCH
18th Apr 20077:45 amRNSTrading Statement
30th Mar 20079:24 amRNSTotal Voting Rights
22nd Mar 20072:47 pmRNSHolding(s) in Company
19th Mar 20079:56 amRNSHolding(s) in Company
19th Mar 20079:52 amRNSHolding(s) in Company
19th Mar 20079:51 amRNSHolding(s) in Company
19th Mar 20079:49 amRNSHolding(s) in Company
13th Mar 20073:28 pmRNSAdditional Listing
28th Feb 20071:04 pmRNSTotal Voting Rights
23rd Feb 20077:01 amRNSAdditional Listing
21st Feb 20077:01 amRNSDirector/PDMR Shareholding
8th Feb 20073:54 pmRNSAdditional Listing
5th Feb 20072:52 pmRNSHolding(s) in Company
19th Jan 20072:30 pmRNSTotal Voting Rights
12th Jan 20073:07 pmRNSIssue of Equity
14th Dec 20065:00 pmRNSTotal Voting Rights
11th Dec 20067:00 amRNSInterim Results
27th Nov 20069:32 amRNSBoard Appointment
14th Nov 20067:03 amRNSSynergy Healthcare Agreement
1st Nov 20067:01 amRNSIssue of Equity
26th Oct 20061:12 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 20061:02 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200612:28 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200610:24 amRNSDistribution Agreements
16th Oct 20067:01 amBUSByotrol Plc: Result of Byotrol Use in Hospital
18th Sep 200610:56 amBUSREPEAT: Byotrol Plc: Chinese Patent Granted and Customer Orders Shipped
18th Sep 200610:30 amBUSByotrol Plc: Chinese Patent Granted and Customer Orders Shipped
11th Sep 20067:01 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.